M
Maxime Dougados
Researcher at University of Paris
Publications - 1144
Citations - 78022
Maxime Dougados is an academic researcher from University of Paris. The author has contributed to research in topics: Rheumatoid arthritis & Ankylosing spondylitis. The author has an hindex of 134, co-authored 1054 publications receiving 69979 citations. Previous affiliations of Maxime Dougados include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study
Santiago Rodrigues Manica,Alexandre Sepriano,Sofia Ramiro,Fernando P. Santos,Polina Putrik,Elena Nikiphorou,Sam Norton,Anna Molto,Maxime Dougados,Désirée van der Heijde,Robert Landewé,Filip Van den Bosch,Annelies Boonen +12 more
TL;DR: Higher education level and higher country SE welfare are associated with a higher likelihood of keeping patients with SpA employed, and absenteeism and presenteeism are only associated with clinical but not with individual-level or country-level SE factors.
Journal ArticleDOI
Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis
Raphaèle Seror,Florence Tubach,Gabriel Baron,Bruno Falissard,Isabelle Logeart,Maxime Dougados,Philippe Ravaud +6 more
TL;DR: Because of its better responsiveness, ease of use, low missing data rate and ability to highlight patient priorities, the WOMAC top 5 could be an interesting tool in therapeutic evaluation in hip or knee osteoarthritis.
Journal ArticleDOI
Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee: A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam
X Ayral,N. Mackillop,Harry K. Genant,J. Kirkpatrick,André D. Beaulieu,P. Pippingskiöld,R.K. Will,S. Alava,Maxime Dougados +8 more
TL;DR: In this article, the authors test the hypothesis that tenidap has a structure-modifying effect in human knee osteoarthritis and show that there is no statistically significant difference between the treatment arms with regard to the structural progression of medial knee OA as measured by radiography and arthroscopy.
Journal ArticleDOI
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort
TL;DR: Optimal MTX dose is more efficacious than non-optimal dose for remission and function in early arthritis in daily practice, with no impact on radiological progression over 2 years.
Journal ArticleDOI
Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial.
Bruno Fautrel,Mathilde Benhamou,Maxime Breban,Carine Roy,Christelle Lenoir,Gérard Trape,Alain Baleydier,Philippe Ravaud,Maxime Dougados +8 more
TL;DR: The administration of infliximab every 6 weeks is cost effective as compared with a DEM regimen; however, the ICER is close to the acceptability threshold of €50 000 for one QALY gained.